Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) in Lung Adenocarcinoma Patients With Acquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors

NCT01718847 is registered in ClinicalTrials.gov with National OncoVenture as lead sponsor.

NCT NCT01718847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01718847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Exploratory Trial to Evaluate the Efficacy and Safety of NOV120101 (Poziotinib) in Lung Adenocarcinoma Patients With Acquired Resistance to 1st Generation EGFR Tyrosine Kinase Inhibitors
Lead sponsor
National OncoVenture
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2013
Completion date
September 30, 2014
Enrollment
40 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

increased drug resistance